Research Article
A Pyroptosis-Based Prognostic Model for Immune Microenvironment Estimation of Hepatocellular Carcinoma
Figure 7
Drug sensitivity and immune checkpoint gene expression of high-risk and low-risk groups in TCGA. (a) Sorafenib IC50 comparison. (b–g) The immune checkpoint expression comparison, including PDCD1, CD274, CTLA4, HAVCR2, LAG3, and TIGIT (, , and ).
(a) |
(b) |
(c) |
(d) |
(e) |
(f) |
(g) |